lungs

Pfizer has completed pneumonia case accrual in Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) with 65 years of age and older, designed to evaluate Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed] (Prevenar 13).

The primary outcome of the double-blind, randomised, placebo-controlled efficacy trial is the efficacy of Prevenar 13 in preventing CAP caused by the 13 pneumococcal serotypes included in the vaccine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

In the trial, which is an event-driven clinical study, a pre-specified number of communityacquired, vaccine-type pneumococcal pneumonia cases will have to occur among enrolled patients prior to the announcement of results, according to Pfizer.

The trial is being conducted by the University Medical Center Utrecht in the Netherlands.

Pfizer also said that the remaining suspected cases that are currently in review will be fully processed to allow the database to be locked, as detailed in the study protocol.

See Also:

The suspected case analysis will be performed by Julius Clinical, a spin-off of the Julius Center for Health Sciences and Primary Care.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the suspected case analysis period, which is expected to take several months to complete, Pfizer will be blinded to the data.

Following unblinding, the data will be reviewed by Pfizer, Julius Clinical, and the primary investigator and the top-line results are expected to be revealed in early 2014.

In order to accomplish regulatory commitments under the US Food and Drug Administration’s accelerated approval programme, Pfizer initiated the CAPiTA study, which involves about 85,000 subjects.

Image: Lungs with Community-acquired Pneumonia pretreatment. Photo: courtesy of Jtechr.